POMIV-DSR Capsule

POMIV-DSR

PRESENTATION:
Pantoprazole IP 40 mg
Domperidone IP 30 mg

PACKING AVAILABLE:
(10X10) (ALU-ALU)
Pantoprazole with Domperidone is used to reduce the amount of acid produced by the stomach, to treat or prevent conditions such as heartburn, Gastritis, ulcers and GERD.

Indications



Antacids, Antireflux Agents & Antiulcerants / GIT Regulators, Antiflatulents & Anti-Inflammatories.

Mechanism of Action



Pantoprazole:-

Pantoprazole is a potent proton pump inhibitor. It inhibits the H /K ATPase enzyme (proton pump) irreversibly and blocks the final step of acid secretion. The proton pump is responsible for the secretion of HCl into the stomach. Proton pump inhibition blocks acid secretion regardless of whether it originates from stimulation of Acetyl Choline, gastrin, or histamine receptors.

Domperidone:-

Dompeidone is a potent dopamine receptor (D ) antagonist.ncreases motility of g.i. tract by 2 inhibiting the action of dopamine and increases gastric emptying. Domperidone increases lower esophageal sphincter pressure and prevents reflux of stomach contents into esophagus. Domperidone also inhibits the D receptor in the chemoreceptor trigger zone (CTZ) thereby it 2 prevents nausea and vomiting.

Pharmacokinetics



Pantoprazole:-

Pantoprazole is unstable in acid and is administered orally in the form of an enteric-coated tablet. Absorption takes place in the small intestine. On average, the maximum serum/plasma concentrations are approximately2 to 3 micrograms/ml about 2 ½ hrs after administration of 40 mg pantoprazole daily.

Domperidone:-

In man, peak plasma level of domperidone occurs within 30 minutes after oral (fasted) administration. Peak plasma concentrations are 20 ng/ml after a single 10mg tablet, and 70 to 100 ng/ml after oral doses of 60 mg.After oral administration of 40 g 4-domperidone to healthyvolunteers, 31st, of the radioactivityis excreted in the urine and 66 %in the faeces over a period of 4 days.

Adverse Effect



From the above discussion, it can be concluded that this medicine could improve the quality of life of children with allergic rhinitis as well as asthma in addition to being efficacious as immunotherapy in seasonal allergic rhinitis in children aged 2-5 years. Moreover it has a considerable safety profile, with persistent results. Oral doses of this medicine has shown efficacy as a preventive treatment for asthma during clinical trials in children aged 2 — 14 years. This combination offers as effective, well tolerated and convient treatment option for children with asthma and allergies.

Contraindication



Hypersensitivity, pregnant patients, patients with blood and lymphatic system disorder and psychiatric disorder.